These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31732173)

  • 21. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depression in Parkinson's disease: diagnosis and management.
    Latoo J; Mistry M; Dunne FJ
    Br J Hosp Med (Lond); 2012 Jun; 73(6):331-4. PubMed ID: 22875323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unraveling depression in Parkinson's disease.
    Antonini A
    Eur J Neurol; 2008 Sep; 15(9):885-6. PubMed ID: 18796071
    [No Abstract]   [Full Text] [Related]  

  • 24. Managing depression in Parkinson's patients: risk factors and clinical pearls.
    Biemiller R; Richard IH
    Neurodegener Dis Manag; 2014; 4(4):329-36. PubMed ID: 25313989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Correction of anxiety-depressive disorders in Parkinson's Disease.].
    Shuteeva TV; Gorshunova NK
    Adv Gerontol; 2017; 30(5):765-769. PubMed ID: 29322746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clozapine use pattern in persons with and without treatment for Parkinson's disease in real-world conditions: a naturalistic study in a community-based sample.
    Verdoux H; Pambrun E
    Acta Psychiatr Scand; 2014 Dec; 130(6):487-97. PubMed ID: 25302631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reply to letter: Does Parkinson's disease increase the risk of cardiovascular events? A systematic review and meta-analysis.
    Alves M; Caldeira D; Ferro JM; Ferreira JJ
    Eur J Neurol; 2020 Feb; 27(2):e12. PubMed ID: 31710751
    [No Abstract]   [Full Text] [Related]  

  • 28. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report.
    Tagai K; Nagata T; Shinagawa S; Tsuno N; Ozone M; Nakayama K
    Psychogeriatrics; 2013 Jun; 13(2):103-7. PubMed ID: 23909968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depression in Parkinson's disease: identification and management.
    Chen JJ; Marsh L
    Pharmacotherapy; 2013 Sep; 33(9):972-83. PubMed ID: 23798003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis.
    Rocha FL; Murad MG; Stumpf BP; Hara C; Fuzikawa C
    J Psychopharmacol; 2013 May; 27(5):417-23. PubMed ID: 23427193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low adherence to antidepressants is associated with increased mortality in Parkinson disease patients.
    Shoval G; Stubbs B; Balicer RD; Feldman B; Hoshen M; Zalsman G; Sagy R; Hochman E; Weizman A; Krivoy A
    Parkinsonism Relat Disord; 2017 Oct; 43():92-96. PubMed ID: 28797565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.
    Paumier KL; Siderowf AD; Auinger P; Oakes D; Madhavan L; Espay AJ; Revilla FJ; Collier TJ;
    Mov Disord; 2012 Jun; 27(7):880-7. PubMed ID: 22555881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of depression in Parkinson's disease.
    Sawabini KA; Watts RL
    Parkinsonism Relat Disord; 2004 May; 10 Suppl 1():S37-41. PubMed ID: 15109585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reply to Letter to the Editor by William Gooding and Simion Chiosea: Alternate diagnostic test interpretation in a retrospective convenience cohort and clinical application of MPTX.
    Lupo MA; Walts AE; Sistrunk JW; Massoll N; Campbell R; Jackson SA; Toney N; Narick CM; Kumar G; Mireskandari A; Finkelstein SD; Bose S
    Diagn Cytopathol; 2021 Feb; 49(2):349-350. PubMed ID: 33236830
    [No Abstract]   [Full Text] [Related]  

  • 37. [Psychiatric complications of Parkinson's disease: their symptoms and treatment].
    Castro-García A; Sesar-Ignacio A; Ares-Pensado B
    Rev Neurol; 2004 Oct 1-15; 39(7):646-50. PubMed ID: 15490352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depression in Parkinson's disease - a review.
    Wermuth L; Bech P
    Acta Neurol Scand; 2006 Nov; 114(5):360. PubMed ID: 17022788
    [No Abstract]   [Full Text] [Related]  

  • 39. MEDICAL AND SURGICAL TREATMENT OF PARKINSON'S DISEASE.
    MARKHAM CH
    Med Clin North Am; 1963 Nov; 47():1591-601. PubMed ID: 14078551
    [No Abstract]   [Full Text] [Related]  

  • 40. Letter to the editor: Parkinson's disease and early subthalamotomy.
    Guridi J; Obeso JA
    J Neurosurg; 2015 Apr; 122(4):980-1. PubMed ID: 25679280
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.